Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · Real-Time Price · USD

5.56

+0.78 (16.32%)

At close: Jun 6, 2025, 4:00 PM

5.49

-0.07 (-1.26%)

After-hours: Jun 6, 2025, 6:04 PM EDT

Sagimet Biosciences Employees

Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.

Employees

14

Change (1Y)

4

Growth (1Y)

40.00%

Revenue / Employee

n/a

Profits / Employee

-$4,079,571

Market Cap

179.01M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	4	40.00%
Dec 31, 2023	10	0	-
Dec 31, 2022	10	3	42.86%
Dec 31, 2020	7	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

SGMT News

2 days ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha
2 days ago - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - GlobeNewsWire
15 days ago - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 - GlobeNewsWire
4 weeks ago - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
3 months ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
3 months ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
3 months ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha
7 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha